Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients

[1]  Song-Cheol Kim,et al.  Pharmacokinetic Study of Mycophenolic Acid in Korean Kidney Transplant Patients , 2004, Journal of clinical pharmacology.

[2]  M. Pescovitz,et al.  Equivalent Pharmacokinetics of Mycophenolate Mofetil in African‐American and Caucasian Male and Female Stable Renal Allograft Recipients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Klinger,et al.  The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. , 2003, Transplantation proceedings.

[4]  L. Shaw,et al.  Monitoring of Mycophenolic Acid in Clinical Transplantation , 2002, Therapeutic drug monitoring.

[5]  L. Shaw,et al.  Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. , 2000, Therapeutic drug monitoring.

[6]  G. Filler,et al.  Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression , 2000, Pediatric Nephrology.

[7]  W. Weimar,et al.  Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. , 1999, Transplantation.

[8]  D. Nicol,et al.  The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[9]  A. Tsaroucha,et al.  Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. , 1999, Therapeutic drug monitoring.

[10]  L. Shaw,et al.  Therapeutic monitoring of mycophenolic acid: A consensus panel report , 1998 .

[11]  A. Tsaroucha,et al.  Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. , 1997, Transplant immunology.

[12]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[13]  M. Hale,et al.  Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. , 1996, Transplantation proceedings.

[14]  M. Hale,et al.  Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration , 1996, Journal of clinical pharmacology.

[15]  L. Shaw,et al.  Mycophenolate Mofetil: A Report of the Consensus Panel , 1995, Therapeutic drug monitoring.

[16]  J. Ransom.  Mechanism of Action of Mycophenolate Mofetil , 1995, Therapeutic drug monitoring.

[17]  European Cooperative Study Group.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection , 1995, The Lancet.

[18]  S. Suzuki,et al.  Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan. , 1995, Transplantation proceedings.

[19]  C. Young,et al.  RS-61443: a new immunosuppressive agent. , 1994, Transplantation proceedings.

[20]  W. Sadee,et al.  Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. , 1985, Cancer research.

[21]  Y. Matsuzawa,et al.  Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. , 1984, Journal of pharmacobio-dynamics.